Table 2.

Evaluation of target coverage and conformity, intermediate dose‐spillage and GTV nodal doses for all 8‐LNs SBRT patients (17 nodes) for both plans.

	Parameters	Halcyon VMAT	TrueBeam VMAT
Combined PTV	Volume covered by Rx dose (%)	95.0	95.0
	CI	1.05 ± 0.1 (0.99–1.15)	1.07 ± 0.1 (0.98–1.22)
Intermediate dose‐spillage	D2cm	50.5 ± 6.8 (39.5–58.7)	51.0 ± 6.9 (42.0–60.2)
GTV coverage (n = 17)	Minimum dose (%)	101.1 ± 1.4 (99.7–104.0)	100.6 ± 2.2 (97.8–104.9)
	Maximum dose (%)	108.3 ± 1.4 (106.0–110.5)	108.2 ± 2.5 (105.5–112.5)
	Mean dose (%)	104.3 ± 1.1 (103.2–105.8)	104.0 ± 1.8 (102.0–107.5)

Dose was 25 Gy to 36.25 Gy in 5 fractions to each abdominal/pelvic LN. Mean ± SD (range) was reported.

SD, standard deviation; n, no. of GTV.